Drug Discovery & DDS– category –
-
Nature Communications: AI-Powered RCDO Framework Integrates Molecular Generation and Experimental Feedback to Accelerate Drug Discovery
Nature Communications Unknown Overview A groundbreaking closed-loop reinforcement learning framework, Rapid Compound Directed Optimization (RCDO), has been unveiled in a new Nature Communications paper for drug discovery. RCDO seamlessly... -
FDA Approves Lisraya (Brepocitinib) as First Oral JAK Inhibitor for Adult Dermatomyositis, Efficacy & Safety Confirmed in Phase 3 Trial of 241 Patients
FDA USA Overview The US FDA has approved Lisraya (brepocitinib) tablets as the first oral treatment for adult dermatomyositis. Granted Orphan Drug and Priority Review designations, this JAK pathway inhibitor effectively reduces inflammat... -
Structure Therapeutics’ Oral GLP-1 Aleniglipron Achieves 16.3% Weight Reduction in Phase 2, Advances to Phase 3 Amidst Robust Obesity Pipeline
Becker's Hospital Review Unknown Overview A pipeline update on 13 experimental weight-loss drugs highlights Structure Therapeutics' oral GLP-1 agent, Aleniglipron, which demonstrated a remarkable 16.3% placebo-adjusted weight reduction i... -
Samsung Biologics to Acquire PolyPeptide Group for $1.8B, Expanding CDMO Capabilities into Peptide Therapeutics with $2.2B Capital Raise
Endpoints News South Korea Overview Samsung Biologics announced a capital raise of nearly $2.2 billion to fund its long-term growth strategy, including the acquisition of PolyPeptide Group for $1.8 billion. This acquisition will signific... -
Pin Therapeutics Unveils Oral CK1α Molecular Glue Degrader PIN-5018 for Adenoid Cystic Carcinoma at China TPD Forum, Phase 1 Underway Targeting FDA Accelerated Approval
Korea Biomedical Review South Korea Overview Pin Therapeutics presented PIN-5018, an oral CK1α-selective molecular glue degrader for adenoid cystic carcinoma (ACC), derived from its proprietary PinMARS platform, at the China Targeted Pro... -
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C... -
Oral Absorption of Therapeutic Peptides Remains Below 1%, MDPI Review Identifies Enzymatic Degradation, pH, Microbiota as Key Barriers
MDPI Unknown Overview A new MDPI review provides a comprehensive analysis of the complex physiological determinants influencing the oral absorption of therapeutic peptides. It confirms that the bioavailability of oral peptides typically ... -
Clinical Landscape of Targeted Protein Degradation Explored, Molecular Glues Show Faster Progress with Nanomedicine Delivery Strategies
MDPI Unknown Overview A new review analyzes the clinical landscape of targeted protein degradation (TPD), focusing on PROTACs and molecular glue degraders, noting that the smaller molecular size of molecular glues may enable faster clini... -
University of Virginia Pioneers Focused Ultrasound for Temporary Blood-Brain Barrier Opening, Redefining Drug Size Impact on Delivery
Physics World USA Overview Researchers at the University of Virginia have developed a pioneering method using focused ultrasound (FUS) to temporarily open the blood-brain barrier (BBB) for drug delivery to the brain. Utilizing MRI physic... -
Nanotechnology Overcomes Drug Delivery Challenges: Liposomes & Polymeric Nanoparticles Enhance Drug Solubility and Targeted Delivery
Scientific Review Unknown Overview A recent review highlights nanotechnology's transformative role in overcoming traditional drug delivery challenges, such as poor solubility and non-specific distribution. Diverse nanocarriers, including...
